Pharmacy-based PrEP Delivery in Kenya

Last updated: December 18, 2024
Sponsor: Fred Hutchinson Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hiv

Treatment

Counselor-supported delivery of pharmacy PrEP/PEP

Implementor-sustained delivery of pharmacy PrEP/PEP

Referral to clinic-based PrEP/PEP

Clinical Study ID

NCT05842122
RG1123165
BMGF INV-033052
11136
  • Ages > 16
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A cluster-randomized control trial (cRCT) testing different cost-sharing models for the delivery of HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) services at private pharmacies in Kenya. The goal is to assess the effect of different pharmacy-based PrEP/PEP service delivery models on PrEP/PEP initiation and continuation outcomes, compared to pharmacy referral to clinic-based PrEP/PEP services (i.e., what is currently allowed in Kenya at the moment without any changes to policies or guidelines). In the cRCT, 60 pharmacies across Central and Western Kenya will be randomized to one of 4 study arms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Pharmacies

  • Registered with the Pharmacy and Poisons Board (PPB)

  • Must have at least one full-time licensed pharmacist or pharmaceutical technologiston staff

  • Must have a private room where HIV testing and PrEP/PEP counseling can occur

  • Must be willing to use a study-specific module within a digital platform (MaishaMeds) to record pharmacy PrEP/PEP dispensing

  • Owner must agree to allow a trained research assistant to come to the pharmacy onselect days to collect data from a random subset of participants

  • Owner must agree to allow providers to participate in a monitored WhatsApp group,optional surveys, and optional in-depth interview

  • Owner must agree to allow providers to routinely engage with a technical assistant

Pharmacists/HTS counselors

  • ≥ 18 years old

  • Licensed pharmacist, licensed pharmaceutical technologist, or NASCOP-certified HTScounselor

  • Willing to provide PrEP and PEP services, including HIV testing and associatedcounseling services

  • Completed training on PEP/PrEP service delivery at pharmacies, includingcertification for rapid diagnostic testing

  • Able and willing to provide informed consent

  • Complete study training

  • Willing to use a study-specific module within a digital platform (Maisha Meds) todocument PrEP/PEP services rendered

Clients

  • ≥ 16 years old

  • Interested in being screened for PrEP or PEP

  • Meets all criteria to be eligible for pharmacy-delivered PrEP or PEP on thePrescribing Checklist, including being at risk for HIV and not having any medicalconditions that might contraindicate PrEP safety

  • Able and willing to provide informed consent

Exclusion

Exclusion Criteria:

Clients

  • Unwilling to provide a phone number at which an RA can reach them for completingsurveys and communicate important study-related information

  • Currently enrolled in any other HIV vaccine or prevention trial

  • Have a condition that would preclude provision of informed consent, make studyparticipation unsafe, complicate interpretation of outcome data, or otherwiseinterfere with achieving study objectives

Study Design

Total Participants: 5944
Treatment Group(s): 9
Primary Treatment: Counselor-supported delivery of pharmacy PrEP/PEP
Phase:
Study Start date:
June 20, 2023
Estimated Completion Date:
June 20, 2025

Study Description

Participating study pharmacies will be 1:1:1:1 randomized to either: 1) client-sustained delivery of pharmacy PrEP/PEP services (clients pay 250 KES/visit; study team compensates pharmacies 0 KES/visit); implementor-sustained delivery of pharmacy PrEP/PEP services (clients pay 0 KES/visit; study team compensates pharmacies 250 KES/visit); 3) Counselor-supported delivery of pharmacy PrEP/PEP services (clients pay 0 KES/visit; study team compensates pharmacies 100 KES/visit); or 4) referral to existing clinic-based PrEP/PEP services (clients pay 0 KES/visit; study team compensates pharmacies 100 KES/visit). The primary cRCT outcomes are PrEP initiation and continuation, assessed 60 days following clients first pharmacy PrEP/PEP visit/referral. We will implement the trial for up to 16 months, or longer, depending on achievement of our primary study objectives.

Connect with a study center

  • Kenya Medical Research Institute

    Kisumu,
    Kenya

    Active - Recruiting

  • Partners in Health & Research Development

    Thika,
    Kenya

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.